IBTROZI Sales Hit $27.5M as Nuvation Bio Posts $45M Quarterly Revenue
NUVB sits 22% above its 52-week low of $3.92.
Summary
Nuvation Bio reported Q3 2026 total revenue of $45.0 million, including $27.5 million in net product revenue from IBTROZI, up 18% quarter-over-quarter. New patient starts held at roughly 160 even as the overall ROS1+ NSCLC TKI market saw new starts fall about 15% sequentially, and 65% of those starts were TKI-naïve — the company says IQVIA claims data now show IBTROZI leading the ROS1 market in new starts and total active patients. The quarter also carries the September sNDA approval that added the 49.7-month median duration of response to the label, four months ahead of the January 4, 2027 target action date, plus the August Fast Track designation for safusidenib in IDH1-mutant glioma. Cash, equivalents and marketable securities stood at $663.4 million at September 30, and the net loss narrowed to $41.9 million, or $(0.12) per share, from $55.8 million a year earlier. The revenue mix is the key read: product sales are still modest relative to the $1.7 billion market cap, and $17.5 million of the quarter's revenue came from collaboration and license agreements, including a $5.0 million Innovent sales milestone. Management hosts a call at 4:30 p.m. ET today.
At the time of this announcement, NUVB was trading at $4.78 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $3.92 to $9.75. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: PR Newswire.